Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 50 for:    "Elephantiasis" | "Anti-Infective Agents"

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01111305
Recruitment Status : Completed
First Posted : April 27, 2010
Results First Posted : June 1, 2017
Last Update Posted : December 5, 2017
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Tracking Information
First Submitted Date  ICMJE April 24, 2010
First Posted Date  ICMJE April 27, 2010
Results First Submitted Date  ICMJE April 27, 2017
Results First Posted Date  ICMJE June 1, 2017
Last Update Posted Date December 5, 2017
Study Start Date  ICMJE April 2010
Actual Primary Completion Date January 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 30, 2017)
Change in Peak Eosinophil Count Measure as a Percent of Baseline Count. [ Time Frame: during the first 7 days of DEC treatment ]
Peak eosinophil count during the first 7 days of treatment as a percent of the baseline count
Original Primary Outcome Measures  ICMJE
 (submitted: April 24, 2010)
Reduction in peak eosinophil count measure during the first 7 days of DEC treatment as a percent of baseline count. [ Time Frame: 7 days ]
Change History Complete list of historical versions of study NCT01111305 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 30, 2017)
  • Frequency of AE's [ Time Frame: 7 days following initiation of DEC treatment ]
    Adverse events during the first week of DEC treatment
  • Markers of Eosinophil Activation Including Levels of Eosinophil Surface Marker Expression and Serum Levels of Eosinophil Granule Proteins [ Time Frame: two years ]
  • Proportion of Subjects Who Clear Blood Microfilariae [ Time Frame: 3, 7, and 28 days after initiation of treatment with DEC ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 24, 2010)
Frequency and severity of AE's, markers of eosinophil activation proportion of subjects who clear blood microfilariae and time to clearance at 3, 7, and 28 days, rate of recurrence of microfilaremia and/or clinical symptoms. [ Time Frame: 2 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Official Title  ICMJE A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection
Brief Summary Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. This randomized, placebo-controlled, double-blind pilot study (conducted at the NIH Clinical Center) will assess whether and to what extent the administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3 times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on microfilarial clearance.
Detailed Description

Background:

Loa loa is a parasitic worm that infects people in West and Central Africa and is spread by the bite of a deerfly. Adult worms (macrofilariae) live under the skin and cause symptoms such as swellings, itching, and hives. Smaller worms (microfilariae) are found in the bloodstream. Diethylcarbamazine (DEC), the recommended medication for Loa loa infection, can produce very serious side effects, especially in people with high numbers of parasites in the blood. Researchers are investigating new treatments for Loa loa that have fewer or less serious side effects. Researchers believe that a certain kind of blood cells called eosinophils, which increase in the blood after DEC treatment, may be one of the causes of the side effects seen with DEC treatment. Reslizumab is a drug that lowers eosinophils in the blood. Giving reslizumab before DEC treatment might prevent the eosinophils from increasing and reduce some of the side effects from DEC.

Objectives:

- To determine whether reslizumab can prevent or reduce the side effects of treatment with DEC for Loa loa infection.

Eligibility:

Screening: Individuals between 18 and 65 years of age who have lived in or traveled to a Loa-endemic region for at least 1 month

Treatment study: Individuals with Loa loa infection and low numbers of parasites in the blood

Design:

This study will last 24 months and will involve several visits to the National Institutes of Health Clinical Center. Participants will be screened with a blood test for Loa loa parasites. Those who have a low number of Loa loa parasites in the blood will be asked to return for a full medical evaluation and the start of the treatment phase. Those who do not have Loa loa parasites in the blood, or those who have a high number of Loa loa parasites in the blood, are not eligible for this study treatment but may be eligible for other parasitic disease studies conducted by the National Institutes of Health.

Participants will have an initial visit with a full physical evaluation, and blood and urine tests (including leukapheresis to provide sufficient numbers of blood cells for testing). Within 1 month of the first visit, participants will have a single infusion of either reslizumab or a placebo. The infusion visit is estimated to last approximately 5 hours. Three to 7 days after the infusion, participants will begin a 21-day course of DEC (taken by mouth) to treat the infection. Participants will stay overnight at the Clinical Center during the first 3 days of treatment with DEC to be monitored for side effects, and will continue to take the DEC at home after the inpatient treatment. A study coordinator will call participants each day to ask about any symptoms or side effects. Participants will be seen for an additional eight outpatient follow-up visits (at days 7, 14, and 28, and months 3, 6, 12, 18, and 24) for evaluation of signs and symptoms of infection.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
Drug assignment (reslizumab vs. placebo) and eosinophil count
Primary Purpose: Treatment
Condition  ICMJE Loiasis
Intervention  ICMJE
  • Drug: Reslizumab
    Other Name: Cinqair
  • Drug: Diethylcarbamazine
    Other Name: Hetrazan, Banocide
  • Other: Placebo
Study Arms  ICMJE
  • Active Comparator: Reslizumab + DEC
    Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
    Interventions:
    • Drug: Reslizumab
    • Drug: Diethylcarbamazine
  • Placebo Comparator: Placebo + DEC
    Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
    Interventions:
    • Drug: Diethylcarbamazine
    • Other: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 3, 2015)
31
Original Estimated Enrollment  ICMJE
 (submitted: April 24, 2010)
300
Actual Study Completion Date  ICMJE September 2017
Actual Primary Completion Date January 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • INCLUSION CRITERIA: (Screening)

A subject will be eligible for participation in the screening portion of this protocol if all of the following criteria apply:

  1. Between 18 and 65 years of age
  2. Residence in or travel to a Loa-endemic region for greater than 1 month

EXCLUSION CRITERIA: (Screening)

A subject will not be eligible for participation in the screening portion of this study if any of the following conditions apply:

  1. Known to be pregnant
  2. Known to be HIV-positive

INCLUSION CRITERIA: (Interventional Study)

A subject will be eligible for participation in the interventional portion of the study only if all of the following criteria apply:

  1. The subject has documented loiasis with 0-5000 microfilariae/mL blood.
  2. The subject agrees to storage of samples for study
  3. A female subject is eligible for this study if she is any of the following:

    • Not pregnant or breast-feeding.
    • Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are post-menopausal, as defined by no menses in greater than or equal to 1 year)
    • Of childbearing potential but agrees to practice effective contraception* or abstinence for 3 months after administration of the investigational study drug (reslizumab or placebo)

      • NOTE: Acceptable methods of contraception may include one or more of the following: 1) male partner who is sterile prior to the female subject s entry into the study and is the sole sexual partner for the female subject; 2) implants of levonorgestrel; 3) injectable progestogen, an intrauterine device with a documented failure rate of less than 1percent; 4) oral contraceptives; and 5) double barrier methods including diaphragm or condom with a spermicide.

EXCLUSION CRITERIA: (Interventional Study)

A subject will not be eligible to participate in the interventional portion of the study if any of the following conditions are fulfilled at the time of enrollment:

  1. The subject tests positive for HIV infection or has any other known immunodeficiency.
  2. The subject has a concomitant active infection with Onchocerca volvulus.
  3. The subject has used any other investigational agent within the past 30 days.
  4. The subject has used immunosuppressive agents (as listed in section 8.1) within the past 30 days.
  5. The subject has a history of allergic reaction to any antibody therapy or to DEC.
  6. The subject has chronic kidney or liver disease.
  7. The subject has any condition that, in the Investigator s opinion, places the subject at undue risk by participating in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01111305
Other Study ID Numbers  ICMJE 10-I-0101
100101 ( Other Identifier: NIHCC )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
Study Sponsor  ICMJE National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Amy D Klion, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP